Disc Medicine (IRON) EBITDA (2020 - 2026)

Disc Medicine (IRON) has 7 years of EBITDA data on file, last reported at -$69.5 million in Q1 2026.

• On a quarterly basis, EBITDA fell 74.04% year-over-year to -$69.5 million in Q1 2026; TTM through Mar 2026 was -$265.6 million, a 92.18% decrease from a year earlier, with the FY2025 full-year figure at -$236.0 million, down 81.95% from the prior year.
• EBITDA for Q1 2026 stood at -$69.5 million, down from -$67.0 million in the prior quarter.
• Over the last five years, EBITDA for IRON reached as high as -$10.0 million in Q1 2022 and fell as low as -$69.5 million in Q1 2026.
• Historically, EBITDA has averaged -$33.8 million across 5 years, with a median of -$30.9 million in 2024.
• On a YoY basis, EBITDA climbed as much as 43.2% in 2022 and fell as far as 173.9% in 2022.
• Year by year, EBITDA stood at -$15.0 million in 2022, then sank by 97.82% to -$29.7 million in 2023, then decreased by 16.28% to -$34.6 million in 2024, then slumped by 93.84% to -$67.0 million in 2025, then fell by 3.81% to -$69.5 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$69.5 million in Q1 2026, -$67.0 million in Q4 2025, and -$67.7 million in Q3 2025.